Document:

<PAGE>

                                                                   EXHIBIT 10.19

                        1997 INCENTIVE AND NON-INCENTIVE

                               STOCK OPTION PLAN

                                       OF
                            NEXELL THEAPEUTICS INC.
                  (FORMERLY NAMED VIMRx PHARMACEUTICALS INC.)

      1.  Purpose of Plan.

          The purpose of this Incentive and Non-Incentive Stock Option Plan
("Plan") is to further the growth and development of VIMRx  Pharmaceuticals Inc.
("Company") and any subsidiaries thereof by encouraging selected employees,
directors and other persons who contribute and are expected to contribute
materially to the Company's success to obtain a proprietary interest in the
Company through the ownership of stock, thereby providing such persons with an
added incentive to promote the best interests of the Company and affording the
Company a means of attracting to its service persons of outstanding ability.

      2.  Stock Subject to the Plan.

          An aggregate of 3,000,000 shares of the Company's Common Stock, $.001
par value ("Common Stock") subject, however, to adjustment or change pursuant to
paragraph 12 hereof, shall be reserved for issuance upon the exercise of options
which may be granted from time to time in accordance with the Plan ("Options").
Such shares may be, in whole or in part, as the committee appointed by the Board
of Directors to administer the Plan (hereinafter, the "Committee") shall from
time to time determine, authorized but unissued shares or issued shares which
have been reacquired by the Company.  If, for any reason, an Option shall lapse,
expire or terminate without having been exercised in full, the unpurchased
shares covered thereby shall again be available for purposes of the Plan.

      3.  Administration.

          (a) Except as provided in paragraph (c) below, the Plan shall be
administered by the Committee.  The Board of Directors shall appoint the
Committee from among its members.  Such Committee shall be composed of two or
more Directors who, to the extent practicable, shall be "outside directors" as
defined in regulations under Section 162(m) of the Internal Revenue Code of
1986, as amended (the "Code"), and "non-employee directors" as defined by
Regulation 240.16b-3 under the Securities Exchange Act of 1934, as amended.
Such Committee shall have and may exercise any and all of the powers relating to
the administration of the Plan and the grant of Options thereunder as are set
forth in subparagraph 3(b) hereof as the Board of Directors shall confer and
delegate.  The Board of Directors shall have power at any time to fill vacancies
in, to change the membership of, or to discharge such Committee.  The Committee
shall select one of its members as its chairman and shall hold its meetings at
such time and at such places as it shall deem advisable.  A majority of such
Committee shall constitute a quorum and such majority shall determine its
action.  Any action may be taken without a meeting by written consent of all the
members of the Committee.  The Committee shall keep minutes of its proceedings
and shall report the same to the Board of Directors at the meeting next
succeeding.

          (b) The Committee shall administer the Plan and, subject to the
provisions of the Plan, shall have sole authority in its discretion to determine
the persons to whom, and the time or times at which, Options shall be granted;
the number of shares to be subject to each such Option; the provisions regarding
exercisability of each Option; the expiration date of each Option; whether the
Option shall contain a "cashless exercise" provision; whether all or any portion
of the Options shall be incentive stock options ("Incentive Options") qualifying
under Section 422A of the Code or stock options which do not so qualify ("Non-
Incentive Options"); whether a Non-Incentive Option shall have limited
transferability as permitted under the Plan; and whether a Non-Incentive Option
granted to a non-employee shall terminate following the non-employee's
termination of engagement in performing services for the Company or its
subsidiaries pursuant to Section 9 of the Plan.  Both Incentive Options and Non-
Incentive Options may be granted to the same person at the same time provided
each
<PAGE>

type of Option is clearly designated. In making such determinations, the
Committee may take into account the nature of the services rendered by such
persons, their present and potential contribution to the Company's success and
such other factors as the Committee in its sole discretion may deem relevant.
Subject to the express provisions of the Plan, the Committee shall also have
authority to interpret the Plan; to prescribe, amend and rescind rules and
regulations relating thereto; to determine the terms and provisions of the
respective Option Agreements, which shall be substantially in the forms attached
hereto as Exhibit A and Exhibit B; to amend the provisions of outstanding
Options to provide for accelerated exercisability or the extension of the
expiration date of such Options; and to make all other determinations necessary
or advisable for the administration of the Plan, all of which determinations
shall be conclusive and not subject to review.

          (c) The Board of Directors may administer the Plan, in lieu of and
with the same powers as the Committee, with respect to any Options granted or to
be granted under the Plan, provided that such administration is consistent with
the provisions of Section 162(m) of the Code.

      4.  Eligibility for Receipt of Options.

          (a) Incentive Options.  Incentive Options may be granted only to
employees (including officers) of the Company and/or any of its subsidiaries.  A
director of the Company or any subsidiary who is not an employee of the Company
or of one of its subsidiaries is not eligible to receive Incentive Options under
the Plan.  Further, Incentive Options may not be granted to any person who, at
the time the Incentive Option is granted, owns (or is considered as owning
within the meaning of Section 425(d) of the Code) stock possessing more than 10%
of the total combined voting power of all classes of stock of the Company or any
subsidiary (10% Owner), unless at the time the Incentive Option is granted to
the 10% Owner, the option price is at least 110% of the fair market value of the
Common Stock subject thereto and such Incentive Option by its terms is not
exercisable subsequent to five years from the date of grant.  The aggregate fair
market value (determined as of the time an Incentive Option is granted) of the
shares of the Company's Common Stock initially purchasable upon exercise of an
Incentive Option during any calendar year may not exceed $100,000.

          (b) Non-Incentive Options.  Non-Incentive Options may be granted to
any employees (including employees who have been granted Incentive Options),
directors, consultants, agents, independent contractors and other persons whom
the Board of Directors (or Committee) determines will contribute to the
Company's success.

          (c) The maximum number of shares that may be subject to options under
this Plan granted during any calendar year to any executive officer of the
Company is 800,000 shares.

          (d) In the event an outstanding Incentive Option or a portion thereof
no longer qualifies as an incentive stock option under Section 422A of the Code,
such Option or portion thereof, as applicable, thereafter shall be deemed a Non-
Incentive Option under the Plan.

      5.  Option Price.

          The purchase price of the shares of Common Stock under each Option
shall be determined by the Committee, which determination shall be conclusive
and not subject to review, but in no event shall the purchase price be less than
100% of the fair market value of the Common Stock on the date of grant in the
case of Incentive Options (110% of fair market value in the case of Incentive
Options granted to a 10% Owner) and 50% of the fair market value of the Common
Stock on the date of the grant in the case of Non-Incentive Options.

          For purposes of the Plan, unless the Committee determines otherwise,
the "fair market value" of a share of Common Stock as of a certain date shall be
the closing sale price of the Common Stock on The Nasdaq Stock Market or, if the
Common Stock is not then traded on The Nasdaq Stock Market, such national
securities exchange on which the Common Stock is then traded, on the trading
date immediately preceding the date the fair market value is being determined.
The Committee may make such other
<PAGE>

determination of fair market value, based on other factors, as it shall deem
appropriate.

          For purposes of the Plan, the date of grant of an Option shall be the
date on which the Committee shall by resolution duly authorize such Option.

      6.  Term of Options.

          The term of each Option shall be such number of years as the Committee
shall determine, subject to earlier termination as herein provided, but in no
event more than ten years from the date the Option is granted.

      7.  Exercise of Options.

          (a) Each Option shall be exercisable to the extent determined by the
Committee, but in no event shall an Option be exercisable until at least six
months from the date of grant, except as otherwise provided in Paragraph 13
herein.

          (b) An Option may not be exercised for fractional shares of the
Company's Common Stock.

          (c) Except as provided in paragraphs 9, 10 and 11 hereof, and unless
determined otherwise by the Committee with respect to Non-Incentive Options
granted to non-employees, no Option shall be exercisable unless the holder
thereof shall have been an employee, director, consultant, agent, independent
contractor or other person employed by or engaged in performing services for the
Company and/or a subsidiary continuously from the date of grant to the date of
exercise.

          (d) The exercise of an Option shall be contingent upon receipt from
the holder thereof of a written representation that at the time of such exercise
it is the optionee's then present intention to acquire the Option shares for
investment and not with a view to the distribution or resale thereof (unless a
Registration Statement covering the shares purchasable upon exercise of the
Options shall have been declared effective by the Securities and Exchange
Commission) and upon receipt by the Company of cash, or a check to its order,
for the full purchase price of such shares.  The Committee may, in its
discretion, include a "cashless exercise" provision in the applicable Option
Agreement, in which event the optionee will be permitted (i) to deliver
previously owned shares of Common Stock with a fair market value equal to the
exercise price in payment of the full purchase price of such shares, or (ii) to
request that the Company withhold shares of Common Stock issuable upon exercise
of such Option with a fair market value equal to the exercise price of the
shares being purchased under the Option (thereby reducing the number of shares
issuable upon exercise of the Option).

          (e) The holder of an Option shall have none of the rights of a
stockholder with respect to the shares purchasable upon exercise of the Option
until a certificate for such shares shall have been issued to the holder upon
due exercise of the Option.

          (f) The proceeds received by the Company upon exercise of an Option
shall be added to the Company's working capital and be available for general
corporate purposes.

      8.  Transferability of Options.

          No Option granted pursuant to the Plan shall be transferable otherwise
than by will or the laws of descent or distribution and an Option may be
exercised during the lifetime of the holder only by such holder, provided,
however, that the Committee may provide for transferability of a Non-Incentive
Option to an optionee's family members or family trusts.

      9.  Termination of Employment or Engagement.

          (a) Except as provided in paragraph (b) below, in the event the
employment of the holder of an Option shall be terminated by the Company or a
subsidiary for any reason other than by reason of death or disability, or the
engagement of a non-employee holder of a Non-Incentive Option shall be
terminated by
<PAGE>

the Company or a subsidiary for any reason, such holder may, within three months
from the date of such termination, exercise such Option to the extent such
Option was exercisable by such holder at the date of such termination.
Notwithstanding the foregoing, no Option may be exercised subsequent to the date
of its expiration. Absence on leave approved by the employer corporation shall
not be considered an interruption of employment for any purpose under the Plan.
In addition, at the discretion of the Committee, the exercisability of an
outstanding Non-Incentive Option may be extended to a date determined by the
Committee but not beyond ten years from the date of grant.

          (b) The Committee may, in its discretion, at the time of grant or by
amending the applicable outstanding Non-Incentive Option, delete the foregoing
termination provision with respect to a Non-Incentive Option granted to a non-
employee of the Company or its subsidiaries.

          (c) Nothing in the Plan or in any Option Agreement granted hereunder
shall confer upon any Optionholder any right to continue in the employ of the
Company or any subsidiary or obligate the Company or any subsidiary to continue
the engagement of any Optionholder or interfere in any way with the right of the
Company or any such subsidiary to terminate such Optionholder's employment or
engagement at any time.

     10.  Disability of Holder of Option.

          If the employment of the holder of an Option shall be terminated by
reason of such holder's disability, such holder may, within twelve months from
the date of such termination, exercise such option to the extent such Option was
exercisable by such holder at the date of such termination. Notwithstanding the
foregoing, no Option may be exercised subsequent to the date of its expiration.

     11.  Death of Holder of Option.

          If the holder of any Option shall die while in the employ of, or while
performing services for, the Company or one or more of its subsidiaries (or
within six months following termination of employment due to disability), the
Option theretofore granted to such person may be exercised, but only to the
extent such Option was exercisable by the holder at the date of death (or, with
respect to employees, the date of termination of employment due to disability)
by the legatee or legatees of such person under such person's Last Will, or by
such person's personal representative or distributees, within twelve months from
the date of death but in no event subsequent to the expiration date of the
Option.

     12.  Adjustments Upon Changes in Capitalization.

          If at any time after the date of grant of an Option, the Company shall
by stock dividend, split-up, combination, reclassification or exchange, or
through merger or consolidation or otherwise, change its shares of Common Stock
into a different number or kind or class of shares or other securities or
property, then the number of shares covered by such Option and the price per
share thereof shall be proportionately adjusted for any such change by the
Committee whose determination thereon shall be conclusive.

     13.  Acceleration of Exercisability Upon Change in Control.

          Upon the occurrence of a "change in control" of the Company (as
defined below), all outstanding Options shall become immediately fully
exercisable.  For purposes of the Plan, a "change in control" of the Company
shall mean (i) the acquisition at any time by a "person" or "group" (as such
terms are used Sections 13(d) and 14(d)(2) of the Exchange Act of beneficial
ownership (as defined in Rule 13d-3 under the Exchange Act), directly or
indirectly, of securities representing 50% or more of the combined voting power
in the election of directors of the then outstanding securities of the Company
or any successor or the Company; (ii) the termination of service of directors,
for any reason other than death, disability or retirement from the Board of
Directors, during any period of two consecutive years or less, of individuals
who at the beginning of such period constituted a majority of the Board of
Directors, unless the election of or nomination for election of each new
director during such period was approved by a vote of at least two-thirds of the
directors still in office who were directors at the beginning of the period;
(iii)
<PAGE>

approval by the stockholders of the Company of any merger, consolidation, or
statutory share exchange as a result of which the Common Stock shall be changed,
converted or exchanged (other than a merger, consolidation or share exchange
with a wholly-owned Subsidiary) or liquidation of the Company or any sale or
disposition of 80% or more of the assets or earning power or the Company; or
(iv) approval by the stockholders of the Company of any merger, consolidation,
or statutory share exchange to which the Company is a party as a result of which
the persons who were stockholders immediately prior to the effective date of the
merger, consolidation or share exchange shall have beneficial ownership of less
than 50% of the combined voting power in the election of directors of the
surviving corporation; provided, however, that no change in control shall be
deemed to have occurred if, prior to such time as a change in control would
otherwise be deemed to have occurred, the Company's Board of Directors deems
otherwise.

     14.  Vesting of Rights Under Options.

          Neither anything contained in the Plan nor in any resolution adopted
or to be adopted by the Committee, the Board of Directors or the stockholders of
the Company shall constitute the vesting of any rights under any Option.  The
vesting of such rights shall take place only when a written Option Agreement,
substantially in the form of the Incentive Stock Option Agreement attached
hereto as Exhibit A or the Non-Incentive Stock Option Agreement attached hereto
as Exhibit B, shall be duly executed and delivered by and on behalf of the
Company and the person to whom the Option shall be granted.

     15.  Withholding Taxes.

          Whenever under the Plan shares are to be issued in satisfaction of the
exercise of Options granted thereunder, the Company shall have the right to
require the recipient to remit to the Company an amount sufficient to satisfy
federal, state and local withholding tax requirements prior to the delivery of
any certificate or certificates for such shares.

     16.  Termination and Amendment.

          The Plan, which was adopted by the Board of Directors on February 6,
1997 and is subject to stockholder approval, shall terminate on February 6, 2007
and no Option shall be granted under the Plan after such date.  The Board of
Directors may at any time prior to such date terminate the Plan or make such
modifications or amendments thereto as it shall deem advisable, provided,
however, that shareholder approval shall be required:

          (i)   to increase the number of shares reserved for issuance under the
                Plan;

          (ii)  materially increase the benefits accruing to participants under
                the Plan;

          (iii) materially modify the requirements of eligibility for
                participation in the Plan; or

          (iv)  if otherwise required to comply with the incentive stock option
                provisions of Section 162(m) of the Code or the listed company
                requirements of The Nasdaq Stock Market or of a national
                securities exchange on which the Common Stock is then traded,

and, provided, further, that no modification or amendment shall adversely affect
the rights of a holder of an Option previously granted under the Plan without
such holder's written consent.<PAGE>

                                                                   EXHIBIT 10.52

                                VOTING AGREEMENT

This Voting Agreement ("Agreement") is made this 17th day of December 17, 1997
among Baxter Healthcare Corporation, a Delaware corporation ("Baxter"), Lindsay
A. Rosenwald, M.D., an individual ("Rosenwald"), Paramount Capital Asset
Management Inc., a Delaware corporation ("Paramount"), Donald Drapkin, an
individual ("Drapkin"), Richard L. Dunning, an individual ("Dunning"), Laurence
D. Fink, an individual ("Fink"), and Eric A. Rose, an individual ("Rose"), and
any other signatory set forth on the signature page hereto (collectively, the
"Stockholders").

WHEREAS, the Stockholders each hold shares of the common stock (the "Stock") of
VIMRx Pharmaceuticals Inc., a Delaware corporation (the "Company") or options to
acquire Stock; and

WHEREAS, as a condition to Baxter's agreement to sell its immunotherapy business
relating to certain ex vivo cell therapy to the Company (the "Sale"), and as an
inducement for Baxter to enter into the Asset Purchase Agreement, dated as of
October 10, 1997 (the "Asset Purchase Agreement") among the Company, Baxter, and
BIT Acquistion Corp., a Delaware corporation ("Newco"), the Stockholders and
Baxter have agreed to enter into this Agreement, to be specifically enforceable
against each of them, pursuant to which they agree to vote their shares of the
Stock in the manner and for the purpose specified herein.

NOW, THEREFORE, in consideration of the mutual covenants contained herein,, the
Stockholders and Baxter hereby agree as follows:

1. Voting Agreement. (a) Each of the Stockholders hereby agrees to vote all of
the Stock beneficially owned, directly or indirectly, by him or it (and all
Stock issued pursuant to the exercise of stock options) in favor of the Baxter
nominated director in connection with Baxter's right to nominate a director to
the VIMRx Board of Directors pursuant to Section 6.2(E) of the Asset Purchase
Agreement; provided, however, that nothing contained herein shall prevent any
Stockholder from transferring, selling or otherwise disposing of Stock held by
such Stockholder provided any such transferee agrees in a written instrument
satisfactory to Baxter to be bound by the terms hereof; and further provided,
that the obligations of such transferee shall be void as to any transferee
purchasing Stock pursuant to Rule 144 or a registered offering under the
Securities Act of 1933. It is expressly understood and agreed by each of the
Stockholders and Baxter that this Agreement is intended to, and does hereby,
create and constitute a voting agreement within the meaning of Section 218(c) of
the General Corporation Law of the State of Delaware, as amended, and not a
voting trust agreement under Section 218(a) thereof.

     (b)  Baxter hereby agrees to vote all of the Stock beneficially owned,
directly or indirectly, by it in favor of the nominees for director recommended
by VIMRx's Nominating Committee (or by a majority of the Board of Directors if
there is no Nominating Committee); provided, that nothing contained herein shall
require Baxter to refrain from voting its Stock in favor of the Baxter nominated
director; and provided further, that nothing contained herein shall prevent
Baxter from transferring, selling or otherwise disposing of Stock held by Baxter
provided any such transferee agrees in a written instrument satisfactory to
VIMRx to be bound by the terms hereof; and further provided, that the
obligations of such transferee shall be void as to any transferee purchasing
Stock pursuant to Rule 144 or a registered offering under the Securities Act of
1933.

2.  Irrevocable Proxy. (a) In order to secure each Stockholder's obligation to
vote his or its Stock and other voting securities of the Company in accordance
with the provisions of Section 1(a), each Stockholder (other than Baxter) hereby
appoints Baxter (the "Proxy") as its true and lawful proxy and attorney-in-fact,
with full power of substitution, to vote all of his or its Stock and other
voting securities of the Company as expressly provided for in Section 1(a). The
Proxy may exercise the irrevocable proxy granted to it hereunder at any time

                                       1
<PAGE>

any party fails to comply with the provisions of this Agreement. The proxies and
powers granted by each Stockholder pursuant to this Section 2 are coupled with
an interest and are given to secure the performance of the Stockholder's
obligations under this Agreement. Such proxies and powers will be irrevocable
with respect to the matters set forth in Section 1 for the term set forth in
Section 5, and, with respect to any individual, will survive the death,
incompetency and disability of such Stockholder.

     (b)  In order to secure Baxter's obligations to vote its Stock and other
voting securities of the Company in accordance with the provisions of Section
1(b), Baxter hereby appoints the Chief Executive Officer of VIMRx (the "Baxter
Proxy") as its true and lawful proxy and attorney-in-fact, with full power of
substitution, to vote all of Baxter's Stock and other voting securities of the
Company as expressly provided for in Section 1(b). The Baxter Proxy may exercise
the irrevocable proxy granted to him hereunder at any time Baxter fails to
comply with the provisions of this Agreement. The proxy and powers granted by
Baxter pursuant to this Section 2 are coupled with an interest and is given to
secure the performance of Baxter's obligations under this Agreement. Such proxy
and powers will be irrevocable with respect to the matters set forth in Section
1 for the term set forth in Section 5.

3.  Representations of the Parties.  Each party to this Agreement hereby
represents and warrants to each of the other parties that (a) he or it owns and
has the right to vote the number of shares of the Stock set forth opposite his
name on Exhibit A attached hereto, (b) he or it has full power to enter into
this Agreement, and (c) he or it is not a party to any proxy, voting trust or
other agreement which is inconsistent with or conflicts with the provisions of
this Agreement, and no party will grant any proxy or become party to any voting
trust or other agreement which is inconsistent with or conflicts with the
provisions of this Agreement. All representations and warranties contained
herein or made in writing by any party in connection herewith will survive the
execution and delivery of this Agreement, regardless of any investigation made
by any party.

4.  Specific Performance.  The parties hereto agree that irreparable damage
would occur in the event any provision of this Agreement was not performed in
accordance with the terms hereof and that the parties shall be entitled to
specific performance of the terms hereof, in addition to any other remedy at law
or in equity.

5.  Term.  This Agreement shall remain in effect so long as Baxter shall
continue to own at least 3% of the shares of Stock of the Company, as adjusted
for any additional shares of Stock issued by the Company following the date of
this Agreement, and Baxter's obligations hereunder shall continue so long as
Baxter's representative (if Baxter shall have chosen to designate one) shall
retain a seat on the VIMRx Board of Directors.

6.  WAIVER OF JURY TRIAL.  EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES
ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR
RELATING TO THIS AGREEMENT, AND CONSENTS TO THE GRANTING OF SUCH LEGAL OR
EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY THE COURT.

7.  General Provisions.

    (a) All of the covenants and agreements contained in this Agreement shall be
    binding upon, and inure to the benefit of, the respective parties and their
    successors, assigns, heirs, executors, administrators and other legal
    representatives, as the case may be. Nothing contained herein shall prevent
    any of the parties hereto from assigning their rights hereunder.

                                       2
<PAGE>

    (b) This Agreement may be executed in two or more counterparts, each of
    which will be deemed an original but all of which together shall constitute
    one and the same instrument. The parties hereto agree that facsimile
    transmissions of original signatures shall constitute and be accepted as
    original signatures.

    (c) If any provision of this Agreement shall be declared void or
    unenforceable by any court or administrative board of competent
    jurisdiction, such provision shall be deemed to have been severed from the
    remainder of this Agreement and this Agreement shall continue in all
    respects to be valid and enforceable.

    (d) No waiver of any breach of this Agreement extended by any party hereto
    to any other party shall be construed as a waiver of any rights or remedies
    of any other party hereto or with respect to any subsequent breach.

    (e) Whenever the context of this Agreement shall so require, the use of the
    singular number shall include the plural and the use of any gender shall
    include all genders.

    (f) This Agreement shall be governed by and construed in accordance with the
    laws of the State of Delaware, without regard to principles of conflicts of
    law; however, any action or proceeding relating to this Agreement shall be
    brought only in and decided by the federal or state courts in Delaware, such
    courts being a proper forum in which to adjudicate such action or
    proceeding, and each party hereby waives any claim of inconvenient forum.

    (g) The language used in this Agreement shall be deemed to be the language
    chosen by the parties to express their mutual intent and no rule of strict
    construction will be applied against any party.

                                       3
<PAGE>

IN WITNESS WHEREOF, Baxter and each of the Stockholders has executed this
Agreement as of the date first written above.

                           BAXTER HEALTHCARE CORPORATION

                           BY: /s/ Victor W. Schmitt
                           -------------------------

                           Name: Victor W. Schmitt
                           -----------------------

                           Its: President, Venture Management
                           ----------------------------------

                           VIMRx PHARMACEUTICALS INC.

                           By: /s/ Richard L. Dunning
                           --------------------------

                           Name: Richard L. Dunning
                           ------------------------

                           Its: President & CEO
                           --------------------

                           LINDSAY A. ROSENWALD, M.D.

                           /s/ Lindsay A. Rosenwald, M.D.
                           ------------------------------

                           PARAMOUNT CAPITAL ASSET MANAGEMENT INC.

                           By: /s/ Lindsay A. Rosenwald
                           ----------------------------

                           Name: Lindsay A. Rosenwald
                           --------------------------

                           Its: President
                           --------------

                                       4
<PAGE>

                           DONALD DRAPKIN

                           /s/  Donald Drapkin
                           ---  --------------

                           RICHARD DUNNING

                           /s/  Richard Dunning
                           ---  ---------------

                           LAURENCE D. FINK

                           /s/  Laurence D. Fink
                           ---  ----------------

                           ERIC A. ROSE, M.D.

                           /s/  Eric A. Rose, M.D.
                           ---  ------------------

                                       5
<PAGE>

                                   EXHIBIT A

                                 NUMBER OF SHARES OF VIMRx
                                 STOCK THAT STOCKHOLDER HAS
STOCKHOLDER                      RIGHT TO VOTE
                                 -------------

BAXTER HEALTHCARE CORPORATION       11,000,000

LINDSAY A. ROSENWALD, M.D.              50,000

PARAMOUNT CAPITAL ASSET
MANAGEMENT INC.                      3,666,666

DONALD DRAPKIN                         150,000

RICHARD L. DUNNING                       3,595

LAURENCE D. FINK                       433,333

ERIC A. ROSE                           328,400

                                       6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]